Plain-English translation of NCT06066450 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new heart stent called OSFIT that releases medication to help prevent re-blockage in coronary arteries. The stent is designed specifically for blockages that occur right at the opening of heart vessels, which can be tricky to treat. Researchers want to see how well this treatment works and how safe it is over one year of follow-up.
Blockages at the very opening of coronary arteries are harder to treat with standard stents because of their unique location. This study will help doctors understand whether this specialized stent design is effective and safe for this specific type of heart blockage.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the OSFIT stent as part of your normal heart procedure — you won't need extra surgery. After that, you'll be monitored for 12 months with follow-up visits to track how you're doing and whether the stent is working properly. Some participants at two hospitals may also have a special imaging test called OCT performed immediately after the procedure to confirm the stent was placed correctly.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
South Korea
Sponsor
Genoss Co., Ltd.
Enrollment target
~1,000 participants
Started
July 2023
Primary completion
December 2026
Age range
19 Years and older
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
seong-jae TaK, MD, PhD
Ajou University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.